An IAS–USA State-Of-The-Art Clinical Conference
Management of Hepatitis C Virus in the New Era:
Small Molecules Bring Big Changes

NEW YORK VIRAL HEPATITIS COURSE – FRIDAY, APRIL 15, 2011

Course Overview
Grant Support
Agenda
Syllabus Book
Learning Objectives
Continuing Medical Education Information
Registration Information, Deadlines, and Fees
Hotel, Travel, and General Meeting Information

Program Committee:

Susanna Naggie, MD
Assistant Professor of Medicine
Duke University

Marion G. Peters, MD
John V Carbone, MD, Endowed Chair
Professor of Medicine
University of California San Francisco

Robert T. Schooley, MD
Professor of Medicine and Vice Chair, Department of Medicine
Head, Division of Infectious Diseases
University of California San Diego

David L. Thomas, MD, PhD
Professor of Medicine
Director, Division of Infectious Diseases
The Johns Hopkins University

 

COURSE OVERVIEW

Assessment of Needs:

IAS–USA has expanded its mission to include activities that relate to the management of viral infections other than HIV. The first phase of these efforts will focus on hepatitis C virus (HCV) infection. Rapid advances in treatment are anticipated with the introduction of direct-acting antivirals (DAAs) to the HCV treatment paradigm. With the projected large increase in the number of patients who will require HCV treatment in the near future, clinicians who are experts in the complexities of antiretroviral management are uniquely well positioned to join our hepatology and gastroenterology colleagues in providing care for these patients, in what promises to be an exciting new era in HCV care.

Conflicts of Interest:

Information regarding financial relationships with commercial companies that have interests in the content discussed, is obtained from all parties with control over the activity content (ie, co-chairs, faculty, and IAS–USA staff), and any real or apparent conflicts of interest of those parties are resolved prior to the activity being delivered. Financial affiliations of all those parties are published in the course syllabus. Individuals who refuse to disclose financial interests may not participate in the CME activity.

Who Should Attend:

This course is designed for physicians and other health care practitioners who are experienced in the principles of complex chemotherapy (eg, antiretroviral therapy) and are actively treating or will be treating patients with HCV infection.

Representatives and employees of commercial companies (pharmaceutical, diagnostic, medical products, advertising, insurance, investment, communications firms, etc) must contact the IAS–USA regarding registration procedures.

 

GRANT SUPPORT

In the interest of an objective, balanced, and scientifically rigorous CME program, educational grants are pooled to support this activity. We gratefully acknowledge the below commercial companies for their contributions.

MAJOR SUPPORTERS:
Abbott Laboratories
Merck & Co, Inc
Vertex Pharmaceuticals

Requests for additional educational grants have been made to commercial companies with competing products. Information on additional grant supporters will be posted on the IAS–USA Web site as it becomes available.

 

AGENDA

New York HCV Course Agenda (2011) 

The agenda is updated on an ongoing basis. Please check back periodically for new information.


SYLLABUS BOOK

 

LEARNING OBJECTIVES

Upon completion of the IAS–USA viral hepatitis course, participants will be able to:

• Describe HCV replication and its impact on drug development and treatment strategies

• List key data from clinical trials of direct-acting antivirals in patients with HCV infection who are treatment naive or who have not responded to HCV treatment

• Discuss the mechanisms of HCV resistance

• Implement the treatment plans for HCV-infected patients that consider

  • Clinical trial data on the efficacy and safety of directly acting antivirals
  • Appropriate screening
  • Monitoring for and definition of response
  • Potential drug-drug interactions
  • Management of adverse effects of treatment
  • Data that are still needed to be able to best utilize current and future HCV treatments
• Describe the principles of managing liver disease, including staging and recommendations for monitoring for hepatocellular carcinoma.

 

CONTINUING MEDICAL EDUCATION INFORMATION

Accreditation:

The IAS–USA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:

The IAS–USA designates this educational activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

 

REGISTRATION INFORMATION, DEADLINES, AND FEES

Incomplete applications (missing information, unchecked boxes, no payment included) will be returned for completion, prior to processing. If you have not registered or have not received registration confirmation 2 weeks prior to the course, please contact us to confirm that seating is still available.

Representatives and employees of commercial companies (pharmaceutical, diagnostic, medical products, advertising, insurance, investment, communications firms, etc) must contact the IAS–USA regarding registration procedures.

Registered attendees may access the course syllabus, in PDF format, on our Web site after April 8. Please note: The syllabus is typically more than 100 pages long and may take extra time to download. Please submit requests for cancellation or substitution in writing to the IAS–USA office by April 1.

Contact the IAS–USA:
425 California Street Suite 1450
San Francisco, CA 94104-2120
Phone: (415) 544-9400
Fax: (415) 544-9401

 

HOTEL, TRAVEL, AND GENERAL MEETING INFORMATION

For general venue information, including directions and parking, please click here.